**HARP**

**Project ID:** 265396  
**Funded under:** FP7-HEALTH

---

**Evaluation and impact of screening and treatment approaches for the prevention of cervical neoplasia in HIV-positive women in Burkina Faso and South Africa: HPV in Africa Research Partnership**

From 2010-11-01 to 2014-10-31, closed project | HARP Website

---

**Project details**

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 3 919 769,59</td>
<td>HEALTH.2010.2.4.1-4 - Infectious agents and cancer in Africa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Call for proposal:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 3 000 000</td>
<td>FP7-AFRICA-2010</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>CP-FP-SICA - Small/medium-scale focused research project for specific cooperation actions dedicated to international cooperation partner countries(SICA)</td>
</tr>
</tbody>
</table>

---

**Objective**

The proposal's overall aim is to improve cervical cancer prevention programs for HIV-infected women in Africa, by evaluating the effectiveness and cost-effectiveness of alternative screening strategies, and by developing algorithms leading to earlier detection and management of cervical cancer in these high-risk populations.

The proposal's hypotheses are that: i) the use of simplified point of care diagnostic tests to detect high-risk (HR) HPV DNA, never before evaluated in Africa, alone or combination with other tests in various triage strategies has the potential to improve the coverage of cervical cancer screening in high-risk populations, and that it will prove a cost-effective cervical cancer prevention intervention in the long term; and ii) immune restoration and control of HIV replication through highly active antiretroviral therapy (HAART) or HAART initiation improves clearance of HPV infection among high-risk (HR)-HPV infected women, therefore slowing the development or progression of cervical precursor lesions. These findings may suggest that varying strategies or frequencies of screening may be required for women on HAART or not.

The study will enroll 1200 HIV positive women (half on HAART or about to start HAART; and half with high CD4 count>350) in Burkina Faso and South Africa in a cross-sectional evaluation of cervical cancer screening strategies, from which about 1100 HIV-infected women without CIN2+ will be followed at one year to detect incident CIN2+ and persistence, incidence and clearance of HR HPV. A costing and modelling studies will determine the cost-effectiveness of triage strategies targeting HIV+ women.

---

**Related information**

<table>
<thead>
<tr>
<th>Result In Brief</th>
<th>Cervical cancer screening</th>
</tr>
</thead>
</table>
Coordinator
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
KEPPEL STREET
WC1E7HT LONDON
United Kingdom
EU contribution: EUR 694 994
See on map

Activity type: Higher or Secondary Education Establishments

Administrative contact: Frankie Liew
Tel.: +442079588235
Fax: +442074365389
E-mail
Contact the organisation

Participants
UNIVERSITY OF THE WITWATERSRAND JOHANNESBURG
JAN SMUTS AVENUE 1
2001 JOHANNESBURG
South Africa
EU contribution: EUR 1 237 360
See on map

Activity type: Higher or Secondary Education Establishments

Administrative contact: Violet Parker
Tel.: +27112749273
Fax: +27112749273
E-mail
Contact the organisation

CENTRE DE RECHERCHE INTERNATIONALE POUR LA SANTE
Avenue de l'Universite 221 Secteur 13 Zogona
09 Ouagadougou
Burkina Faso
EU contribution: EUR 621 201

Activity type: Higher or Secondary Education Establishments

Administrative contact: Aminata Karambiri
Tel.: +22650308257
Fax: +22650308258
E-mail
Contact the organisation
UNIVERSITE MONTPELLIER I.
Bd Henri IV,5
34060 MONTPELLIER
France

EU contribution: EUR 446 445

Activity type: Higher or Secondary Education Establishments

Administrative contact: Cara Chan Manville
Tel.: +33467548596
Fax: +33467548597
E-mail

Contact the organisation

Subjects
Medical biotechnology - Medicine and Health - Regional Development

Last updated on 2017-05-26
Retrieved on 2018-10-30

© European Union, 2018